Roxadustat
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Kidney Disease
Conditions
Chronic Kidney Disease, End Stage Renal Disease, Anemia
Trial Timeline
May 18, 2012 → Dec 12, 2019
NCT ID
NCT01630889About Roxadustat
Roxadustat is a phase 2 stage product being developed by Astellas Pharma for Chronic Kidney Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01630889. Target conditions include Chronic Kidney Disease, End Stage Renal Disease, Anemia.
What happened to similar drugs?
20 of 20 similar drugs in Chronic Kidney Disease were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05970172 | Phase 3 | Recruiting |
| NCT04408820 | Pre-clinical | Completed |
| NCT04076943 | Phase 2 | Completed |
| NCT03960489 | Phase 1 | Completed |
| NCT02964936 | Phase 3 | Completed |
| NCT02965040 | Phase 1 | Completed |
| NCT02780726 | Phase 3 | Completed |
| NCT02780141 | Phase 3 | Completed |
| NCT02779764 | Phase 3 | Completed |
| NCT01630889 | Phase 2 | Completed |
| NCT01244763 | Phase 2 | Completed |
| NCT01083888 | Phase 1 | Completed |
Competing Products
20 competing products in Chronic Kidney Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Levofloxacin 500 | Dr. Reddy's Laboratories | Pre-clinical | 23 |
| mRNA-0184 | Moderna | Phase 1 | 0 |
| Lubiprostone + Lubiprostone + Placebo | Dr. Reddy's Laboratories | Phase 3 | 37 |
| macitentan 10 mg | BML, Inc. | Phase 3 | 32 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 29 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 36 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 23 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 35 |
| THB001 | Third Harmonic Bio | Phase 1 | 11 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 26 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 14 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 29 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 40 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 29 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 44 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 35 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 42 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 21 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 27 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 25 |